cagrilintide (AM833) / Novo Nordisk - LARVOL DELTA

REIMAGINE 2: CagriSema vs. Semaglutide or Cagrilintide in T2D on Metformin ± SGLT2i (ADA 2026) - No abstract available

Metabolic Disorders • Type 2 Diabetes Mellitus

Arcuate Hypothalamic Circuits Mediate Acute Cagrilintide-Induced Feeding in Mice (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Metabolic Disorders

AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Metabolic Disorders • Obesity

Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro. (PubMed, J Cachexia Sarcopenia Muscle) - "Incretin-based therapies exert distinct, time and dose-dependent effects on skeletal muscle mitochondrial function. Tirzepatide promoted sustained improvements in mitochondrial respiration under both healthy and lipotoxic conditions, indicating potential benefits for maintaining skeletal muscle bioenergetic function. These findings underscore the need for further mechanistic studies and suggest that tirzepatide may have the potential to support skeletal muscle health in metabolic disease."

Journal • Preclinical • Genetic Disorders • Metabolic Disorders

CAGRILINTIDE-SEMAGLUTIDE (CAGRISEMA) VS SEMAGLUTIDE: SUPERIOR WEIGHT LOSS AND COMPARABLE SAFETY THROUGH SYNERGISTIC AMYLIN-GLP-1 CO-THERAPY: A META-ANALYSIS (ACC 2026) - "Weight loss with CagriSema is greater than semaglutide, with similar safety except more injection-site reactions. Larger, longer studies are needed to establish its role in diverse groups."

Retrospective data • Cardiovascular • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • LEP

CAGRISEMA VERSUS CAGRILINTIDE OR SEMAGLUTIDE MONOTHERAPY AS ANTI-OBESITY MEDICATIONS: A SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS (ACC 2026) - "CagriSema offers a superior efficacy-tolerability balance, achieving the greatest weight loss and cardiometabolic improvements while demonstrating the best gastrointestinal tolerability. Cagrilintide monotherapy is a potent alternative with a distinct safety profile, notably less vomiting than GLP-1RAs. These findings position CagriSema as a leading pharmacotherapy for obesity, particularly for patients requiring significant weight loss and improved glycemic control, though long-term outcomes warrant further investigation."

Monotherapy • Retrospective data • Review • Genetic Disorders • Obesity

Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. (PubMed, Diabetes Obes Metab) - "Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dual-agonist therapy for obese patients."

Journal • Retrospective data • Genetic Disorders • Obesity

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. (PubMed, Peptides) - "The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy...Amongst these agents is the dual AMYR/ calcitonin-receptor (CTR) agonist, cagrilintide that has also been co-formulated into a once weekly subcutaneous injection with the long-acting glucagon-like peptide-1receptor (GLP-1R) agonist, semaglutide (CagriSema)...Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234...Gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use. Evidence is emerging that long-acting AMYR agonists may show potential therapeutic benefits in treatment of patients with fatty liver..."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Hepatology • Hypertension • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

STABLE CO-FORMULATION OF CAGRILINTIDE AND SEMAGLUTIDE WITH THE BIOCHAPERONE® PLATFORM FOR MULTI-DOSE PEN INJECTORS: ENABLING FLEXIBLE DOSING IN OBESITY TREATMENT (ATTD 2026) - "BC-CagriSema allows multiple-dose injections of Cagrilintide and Semaglutide. This innovation could enhance clinical applicability through flexible titration and long-term treatment adherence in obesity and diabetes care."

Cardiovascular • Diabetes • Genetic Disorders • Obesity

NN9838-8411: Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health (clinicaltrialsregister.eu) - P1 | N=100 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Genetic Disorders • Obesity

RENEW 2: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (clinicaltrials.gov) - P3 | N=330 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes (clinicaltrials.gov) - P1 | N=158 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

NN9833-8242: Weight loss in people living with overweight or obesity following treatment with cagrilintide (clinicaltrialsregister.eu) - P2/3 | N=120 | Active, not recruiting | Sponsor: Novo Nordisk A/S

New P2/3 trial • Genetic Disorders • Obesity

NN9833-8243: Weight loss in people living with overweight or obesity and type 2 diabetes following treatment with cagrilintide (clinicaltrialsregister.eu) - P2/3 | N=130 | Recruiting | Sponsor: Novo Nordisk A/S

New P2/3 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. (PubMed, Am J Cardiol) - "The dual therapy CagriSema, which combines semaglutide with cagrilintide was developed. CagriSema therapy was associated with superior weight reduction compared with semaglutide or placebo. In conclusion, CagriSema achieves greater weight loss than semaglutide or placebo but increases gastrointestinal adverse events, warranting careful tolerability monitoring and longer-term data."

Journal • Monotherapy • Retrospective data • Review • Cardiovascular • Diabetes • Endocrine Disorders • Genetic Disorders • Hepatology • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

RENEW 1: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Novo Nordisk A/S

Adverse events • New P1 trial • Genetic Disorders • Obesity

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. (PubMed, J Pharm Biomed Anal) - "This study provides the first systematic metabolic characterization of pramlintide, cagrilintide and KBP-066. The identified metabolites and LC-MS/MS detection approach offer a foundation for future monitoring of emerging weight-loss peptide hormone analogues in anti-doping contexts."

Journal • Preclinical

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (clinicaltrials.gov) - P3 | N=809 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (clinicaltrials.gov) - P2 | N=270 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Hepatology

Bariatric Surgery in the Era of GLP1RA: A Narrative Review. (PubMed, Adv Ther) - "The real-world effectiveness of GLP1RA is hindered by issues including cost and tolerability. This narrative review discusses strategies to improve the effectiveness of pharmacotherapy and bariatric surgery and posits that bariatric surgery will continue to play an important role in obesity treatment in the GLP1RA era."

Journal • Review • Cardiovascular • Genetic Disorders • Obesity

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight (clinicaltrials.gov) - P3 | N=460 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Genetic Disorders • Obesity

REIMAGINE 2: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (clinicaltrials.gov) - P3 | N=2734 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity. (PubMed, J Obes Metab Syndr) - "Clinically, the synthetic analog pramlintide has been shown to modestly improve glycemic control and induce weight loss in patients with diabetes. More recently, cagrilintide, a long-acting analog, has produced substantial weight reduction in individuals with obesity. Combination therapy with glucagon like peptide-1 receptor agonists has achieved synergistic effects, with weight loss exceeding 15%, positioning amylin analogs as a promising approach for treatment of diabesity-the co-existence of diabetes and obesity. This review summarizes recent advancements and discusses their implications for future therapeutic applications in diabesity management."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (clinicaltrials.gov) - P3 | N=189 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • LEP • LEPR